Biomea Fusion, Inc. Stock Price, News & Analysis

Biomea Fusion (BMEA) has priced its public offering of securities, consisting of 19,450,000 shares of common stock and warrants, plus 550,000 pre-funded warrants with accompanying warrants. The combined offering price is $2.00 per share of common stock with warrant, and $1.9999 for each pre-funded warrant with warrant. The accompanying warrants have an exercise price of $2.50, are immediately exercisable, and expire in 18 months. The offering is expected to generate approximately $40 million in gross proceeds before deductions. Biomea has granted underwriters a 30-day option to purchase up to 3 million additional shares and/or warrants. The offering is expected to close on June 20, 2025, with Jefferies acting as the sole book-running manager.

Biomea Fusion (BMEA), a clinical-stage diabetes and obesity company, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, pre-funded warrants, and accompanying warrants to purchase common stock. Biomea will grant underwriters a 30-day option to purchase up to 15% additional shares and pre-funded warrants. Jefferies is serving as the sole book running manager for the offering, which is expected to close around June 20, 2025. The securities will be offered through an effective shelf registration statement on Form S-3 filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.

Biomea Fusion (NASDAQ: BMEA) presented updated clinical data for BMF-500, their covalent FLT3 inhibitor, in treating relapsed/refractory acute leukemia. The Phase I COVALENT-103 trial included 27 heavily pretreated patients, with 18 having FLT3 mutations. Key findings showed 9 of 11 evaluable FLT3m patients achieved bone marrow blast reduction, with one patient achieving complete remission with incomplete hematologic recovery (CRi) sustained for 6 cycles. The median overall survival was 3.8 months in Arm A and 3.5 months in Arm B, comparing favorably to historical 2.1 months survival. BMF-500 demonstrated good tolerability with no dose-limiting toxicities or QT prolongation. Following dose escalation completion, Biomea plans to conclude internal development and seek strategic partnerships for the program's advancement.

Biomea Fusion (BMEA) announced that preliminary Phase I data for BMF-500, their covalent FLT3 inhibitor, will be presented at the EHA 2025 Congress in Milan. The COVALENT-103 trial shows promising results in relapsed/refractory acute leukemia patients. Key findings include:

• 24 patients enrolled, with 15 having FLT3 mutations
• 81.8% of evaluable patients showed clinical activity
• 77.8% demonstrated decreased bone marrow blasts
• Median overall survival of 3.48 months vs. historical 2.1 months
• Well-tolerated safety profile with no treatment-related discontinuations

Despite these positive results, Biomea plans to conclude internal development of BMF-500 in oncology and is seeking strategic partnerships, as the company shifts focus to metabolic diseases.

Biomea Fusion (BMEA) announced a strategic realignment in Q1 2025, focusing on its core diabetes and obesity programs while implementing cost-reduction measures. The company reported a net loss of $29.3M for Q1 2025, with cash reserves of $36.2M expected to fund operations into Q4 2025. Key initiatives include a 35% workforce reduction and facility consolidation. The company is prioritizing development of icovamenib (oral menin inhibitor for diabetes) and BMF-650 (oral GLP-1 receptor agonist). Important upcoming milestones include 52-week Phase II data for icovamenib, FDA discussions for Phase IIb trials, and IND submission for BMF-650 in H2 2025. The company has ceased internal oncology program development and appointed Mick Hitchcock as Interim CEO.

Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to two new employees as part of their inducement package. The grants, approved on March 23, 2025, by the compensation committee, allow the purchase of a total of 30,000 shares of common stock.

The stock options will vest quarterly over a four-year period, with 1/16 of the shares vesting each quarter, contingent on continued employment. These awards were issued under Biomea's 2023 Inducement Equity Plan, which was adopted by the board on November 17, 2023, and comply with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants for new employees.

Biomea Fusion (BMEA) announced Q4 and full year 2024 financial results, highlighting significant progress in its diabetes and obesity programs. The company appointed Mick Hitchcock as Interim CEO and shifted focus exclusively to metabolic disorders, terminating oncology trials. Key highlights include:

The COVALENT-111 study showed promising results for icovamenib in type 2 diabetes, achieving a 1.47% HbA1c reduction in severe insulin deficient patients and 53% increase in C-peptide levels. The drug demonstrated durability and good tolerability with no serious adverse events.

Financial results show cash position of $58.6 million as of December 31, 2024. Net loss was $29.3 million for Q4 2024 and $138.4 million for full year 2024. R&D expenses were $118.1 million for 2024, up from $102.5 million in 2023.

Key 2025 milestones include FDA discussions for late-stage development, 52-week COVALENT-111 data, COVALENT-112 open label data, and BMF-650 IND submission.

Biomea Fusion (NASDAQ: BMEA), a clinical-stage diabetes and obesity medicines company, announced a significant leadership change with board member Mick Hitchcock, Ph.D. appointed as interim CEO, replacing Thomas Butler effective immediately.

Dr. Hitchcock, who has served on Biomea's board since March 2021, brings extensive pharmaceutical experience, including 27 years at Gilead Sciences in various vice president roles and 13 years at Bristol-Myers Squibb. His appointment comes at a important time following positive Phase II data for icovamenib in insulin-deficient patients.

The new interim CEO holds a Ph.D. in microbiology from the University of Melbourne and has significant experience in drug development and commercialization, particularly in antiviral treatments. He currently serves as Past Chair of the University of Nevada, Reno Foundation and as an Adjunct Professor of Microbiology at UNR Medical School.

Biomea Fusion (NASDAQ: BMEA) has presented groundbreaking clinical data for icovamenib, their investigational covalent menin inhibitor, at the ATTD 2025 Conference. The drug demonstrated significant improvement in pancreatic beta-cell function in patients with severe insulin-deficient diabetes.

Key findings include:

• 53% mean increase in C-peptide levels 3 months after the last dose
• Strong correlation between C-peptide increase and HbA1c reduction (r=-0.73, p<0.0001)
• Statistically significant placebo-adjusted mean reduction in HbA1c of 1.47% at Week 26 (p=0.022)
• Enhanced responsiveness to GLP-1-based medicines in preclinical studies

The results suggest icovamenib's potential as a first-in-class, disease-modifying therapy by targeting beta-cell restoration and enhancing insulin secretion, with benefits persisting beyond the treatment period. The treatment shows particular promise for severe insulin-deficient diabetes, affecting over 100 million people worldwide.